I attended the
NEDA conference a year ago. One of the statements I walked away with was
"The current advocacy efforts in the United States occur in an almost complete vacuum of data about the health services utilization of individuals who experience an eating disorder."
-- a quote provided by Dr. Russell Marx during his presentation and attributed to a document by Streigel-Moore.
I am bringing this up because there does need to be not only more data about the health services utilization of individuals who experience an eating disorder, there also needs to be some sort of standardization of this and other ED data so researchers, insurance companies, doctors, therapists, nutritionists and psychiatrists can look at studies and know that the information presented there is in the same "language" as in other studies.
I also believe that the Eating Disorder Community of parents, therapists, psychiatrists, organizations/associations, and those with ED's need to advocate for data collection about the prevalence of ED's, the outcomes of various forms of treatment for ED's, and lists of those therapists, medical doctors, and psychiatrists who are
CURRENT re treatment of ED's.
A simple example would be the hidden difference (unless numbers of participants are revealed within the press release) between information noting there was a 50 percent success rate in a study when there were 20 people involved (meaning 10 successes, 10 not so) and when there is a study with similar results with, say, 4000 people.
Just this past week there was a series of articles in the
New York Times about parity, insurance coverage for eating disorders, and comments about the need for residential treatment of eating disorders (among other topics). A
longer commentary with links to the series of articles in the
New York Times was provided by Dr. Julie O'Toole on this series.
Over the more than twenty years that my loved one has fought anorexia with bulimia subtype (I guess that's the best way to categorize the ED she has), the key factor -- an incredibly important factor -- has been getting her back from the brink of starvation and away from the symptoms that go along with starvation so that she could benefit from the use of therapy (cognitive behavioral, psychoanalytical, and dialectical behavioral therapy).
Here's a description of the symptoms of starvation (
excerpt from Wikipedia, italics mine):
"Individuals experiencing starvation lose substantial fat and muscle mass as the body breaks down these tissues for energy. Catabolysis is the process of a body breaking down its own muscles and other tissues in order to keep vital systems such as the Nervous system and heart muscle functioning. Vitamin deficiency is a common result of starvation, often leading to anemia, beriberi, pellagra, and Scurvy. These diseases collectively can also cause diarrhea, skin rashes, edema,and heart failure.
Individuals are often irritable and lethargic as a result.
Early symptoms include impulsivity, irritability, hyperactivity and possibly submissiveness.
Atrophy(wasting away) of the stomach weakens the perception of hunger, since the perception is controlled by the percentage of the stomach that is empty. Victims of starvation are often too weak to sense thirst, and therefore become dehydrated.
All movements become painful due to muscle atrophy and dry, cracked skin that is caused by severe dehydration. With a weakened body, diseases are commonplace. Fungi, for example, often grow under the esophagus, making swallowing unbearably painful.
The energy deficiency inherent in starvation causes fatigue and
renders the victim more apathetic over time. As the starving person becomes too weak to move or even eat,
their interaction with the surrounding world diminishes."
Is there any wonder that the perceived (by others who make decisions about treatment) will to live has diminished?
I am an avid supporter of those who emphasize that
re-nourishment is the first step back to health.
I know there are people (I was one of them) who can finally get sick and tired of being sick and tired and decide to change their behavior. I also know that at least two of my own blood relatives with eating disorders have not been able to do that (yet). In fact, one is slowly making progress,too! So my experience absolutely should not color whether or not my relatives obtain additional treatment. Yet, people will point to my experience and that of others who succeed and wonder. What "trait" did I get that they did not? Research needs to focus on this. And, very importantly, at least in my case I needed years of ongoing off and on therapy to help me develop a mind-set leading to success even though the ED behaviors no longer overtook me.
Recovery isn't a snap one's fingers or wave the magic wand moment.
So, how is re-nourishment accomplished when a person fights this process of eating but who at the same time is willing to undergo treatment because they want to get well; i.e. they do not want to die? What about those who are so overtaken by the disease that they have lost that core sense of fighting for their precious life? In what kind of environment can this be accomplished if environmental factors outside of a residential treatment setting interfere with the person's ability to "stay with the program" long enough to get re-nourished and "reframed" so to speak? These are important questions on behalf of people for whom the first or even the third in-treatment setting doesn't work.
If a person with cancer wants to live and can obtain hundreds of thousands of dollars worth of treatment in the form of surgery, radiation, and on-going chemotherapy, why is this not also uniformly available to those with an eating disorder, for example anorexia, who have a policy with the same insurance company? to those eligible for Medicaid and Medicare when somewhere in the system there are precedents for care for ED?
Could reliable data, collected using uniform standards assist in obtaining this kind of information in order to justify ongoing treatment? in persuading insurance company policy makers and state and national legislators all the way to the US Supreme Court that such treatment is necessary? This has worked in some States but not in others. More needs to be done.
I am asking these question because there are people in two organizations that I'm aware of right now who are working diligently to develop and apply agreed upon standards to other diseases and who have caught the attention of the FDA.
One is The
Critical Path Institute and the other is
CDISC.
Here is a recent press release about their collaboration regarding the treatment of Alzheimer's, also a disease of the brain.
Tucson, Arizona, October 17, 2011– Critical Path Institute (C-Path) and Clinical Data Interchange Standards Consortium (CDISC) today announced the release of version 1.0 of the Alzheimer’s disease (AD) Therapeutic Area Standard (SDTM AD/Mild Cognitive Impairment User Guide). This was developed for the clinical research community to facilitate analysis and learning from clinical studies for treatment or prevention of AD.
The User Guide outlines a standardized set of data elements so that pharmaceutical companies and other medical researchers can more easily, and consistently, collect data that can be reliably pooled and compared.
Lynn Hudson, PhD, C-Path’s Chief Scientific Officer and Executive Director of C-Path’s Coalition Against Major Diseases (CAMD) noted, “Ultimately, this will result in increased efficiencies so that the U.S. Food and Drug Administration (FDA) and other regulatory agencies can more quickly and accurately review new applications for AD therapies, making it possible for medicines to reach patients more quickly and with greater assurances of safety and effectiveness.”
This is an early and landmark outcome from a joint C-Path/CDISC project to formalize and publish the CDISC AD standard based on the elements used in CAMD’s groundbreaking AD data repository. Collaborators in CAMD, which include global stakeholders from C-Path, CDISC, the AD clinical community, the pharmaceutical industry, government agencies, academia, and patient advocacy associations, reached consensus on the relevant pooled data domains, terminology, and definitions.
Early last year, seven of CAMD’s member organizations agreed to share their data from eleven recent AD clinical research studies and allowed it to be standardized, pooled, and made available to qualified researchers around the world. They invested significant in-kind resources to remap the retrospective data to the new format that is now the CDISC standard. Those organizations included Abbott Laboratories, Alzheimer’s Disease Cooperative Study, AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Johnson Johnson, Pfizer, and sanofi-aventis. C-Path worked with another collaborator, Ephibian, a Tucson, Arizona-based company that specializes in software development, databases, web solutions and information security, to build a secure online data repository.
Today, the database contains data from over 4,100 AD subjects mapped to the CDISC standard. Its level of detail and scope will enable researchers to more accurately project the course of mild cognitive impairment (MCI) as it progresses to AD, thereby enabling the design of more efficient clinical trials that have the maximum chance of demonstrating whether a new treatment is truly safe and effective.
CAMD members and scientists around the world use the database to develop mathematical models to better track the course of MCI and AD in patients generally, as well as in genetically-defined subsets.
Roughly 5.3 million people in the U.S. alone are afflicted with AD, with costs reaching as much as $175 billion annually Worldwide, it afflicts 30 million people, a number that is expected to quadruple by 2050. Halting or slowing the progression of this disease will prevent untold suffering and save tens of billions of dollars every year. “Pooling clinical data is a powerful way to gain new insights and leverage the efforts of companies that are developing new therapies,” said Raymond Woosley, MD, PhD, President and CEO of C-Path. “Scientists around the world can now use the combined, standardized data from clinical trials to better understand the true course of Alzheimer’s disease in patients.”
According to Rebecca Kush, PhD, President and CEO of CDISC, “Standards are essential to ensure that data can be aggregated for high quality research and robust analyses. Their value to companies and scientists increases substantially when they are used at the earliest stages of planning for a clinical trial, in the preparation of the protocol and the case report forms (including eCRFs). Adoption of core CDISC standards and the complementary new AD supplement, will enable far more rapid launch of clinical research studies of AD, and will also minimize or eliminate costly back-end data remapping (legacy data conversion). We are delighted to work with C-Path on this project and look forward to similar initiatives for additional therapeutic areas.”
Bron Kisler, Vice President of Strategic Initiatives of CDISC, pointed out that data standards will promote efficiencies in making progress against this disease. “If one trial cannot be reliably compared to another, we lose valuable information and often repeat costly mistakes. It would be like trying to accurately compare distances when they are variably represented and recorded in miles, kilometers, leagues, yards, and light years. If we are ever going to stave off Alzheimer’s disease, we need to be able to clearly study and learn from every piece of data.”
The mission of C-Path is:
To improve health and save lives by accelerating the development of safe, effective medicines.
The mission of CDISC is:
To develop and support global, platform-independent data standards that enable information system interoperability to improve medical research and related areas of healthcare.
The Core Principles of CDISC are:
Lead the development of standards that improve efficiency while supporting the scientific nature of clinical research.
Recognize the ultimate goal of creating regulatory submissions that allow for flexibility in scientific content and are easily interpreted, understood, and navigated by regulatory reviewers.
Acknowledge that the data content, structure and quality of the standard data models are of paramount importance, independent of implementation strategy and platform.
Maintain a global, multidisciplinary, cross-functional composition for CDISC and its working groups.
Work with other professional groups to encourage that there is maximum sharing of information and minimum duplication of efforts.
Provide educational programs on CDISC standards, models, values and benefits.
Accomplish the CDISC goals and mission without promoting any individual vendor or organization.
This may all seem rather dry. I am highlighting this information about these two organizations because I believe similar collaborations as well as data standards will help organizations such as NEDA and NAMI and FEAST as well as researchers in the area of ED arrive at mutually understandable conclusions about what is needed to help those with eating disorders get on the path to recovery.
There are too many lives at stake here. My loved one's is one of them.
As a postscript - I learned while looking up
Dialectical Behavioral Therapy today (November 6, 2011) for the
guest post by Dr. Marilyn Heins on brain development/choices that a group is actively working to put together a list of therapists who provide this very important treatment. Their qualifications need to be part of the database, IMHO. I am raising this point because again here I believe that the Eating Disorder Community of parents, therapists, psychiatrists, organizations/associations, and those with ED's need to advocate for data collection about the prevalence of ED's, the outcomes of various forms of treatment for ED's, and lists of those therapists, medical doctors, and psychiatrists who are
CURRENT re treatment of ED's.